We are live on ! Find out more
ACM

Atika Capital Management Portfolio holdings

AUM $796M
1-Year Est. Return 167.57%
This Fund
S&P 500
This Quarter Est. Return
+24.25%
1 Year Est. Return
+167.57%
3 Year Est. Return
+553.47%
5 Year Est. Return
+1,283.26%
10 Year Est. Return
+44,203.78%
AUM
$518M
AUM Growth
+$42.9M
Cap. Flow
-$57M
Cap. Flow %
-11.01%
Top 10 Hldgs %
30.31%
Holding
98
New
21
Increased
21
Reduced
22
Closed
25

Top Buys

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$11.4M
2
GOOG icon
Alphabet (Google) Class C
GOOG
+$10.8M
3
THO icon
Thor Industries
THO
+$8.71M
4
CNC icon
Centene
CNC
+$7.27M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$7.27M

Top Sells

Rank Stock Value
1
TWTR
Twitter, Inc.
TWTR
+$8.32M
2
MDCO
Medicines Co
MDCO
+$8.27M
3
DIS icon
Walt Disney
DIS
+$6.25M
4
QTWO icon
Q2 Holdings
QTWO
+$5.91M
5
ROKU icon
Roku
ROKU
+$5.36M

Sector Composition

Rank Sector Weight
1 Healthcare 35.56%
2 Technology 16.92%
3 Consumer Discretionary 12.84%
4 Communication Services 10.59%
5 Financials 4.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
51
Neurocrine Biosciences
NBIX
$16.5B
$4.84M 0.93%
45,000
-12,000
-21% -$1.26M
NBIX icon
52
PUT
Neurocrine Biosciences
NBIX
$16.5B
– –
0
– –
BHVN
53
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$4.63M 0.89%
85,000
+9,000
+12% +$446K
IGIC icon
54
International General Insurance
IGIC
$1.16B
$3.66M 0.71%
+350,000
New +$3.64M
ZGNX
55
DELISTED
Zogenix, Inc.
ZGNX
$3.54M 0.68%
68,000
+25,000
+58% +$1.14M
CHRS icon
56
Coherus Oncology
CHRS
$227M
$3.51M 0.68%
195,000
+9,500
+5% +$175K
EW icon
57
Edwards Lifesciences
EW
$51.1B
$3.27M 0.63%
42,000
+18,000
+75% +$1.41M
KRYS icon
58
Krystal Biotech
KRYS
$9.6B
$3.23M 0.62%
58,319
– –
PODD icon
59
Insulet
PODD
$9.27B
$3.08M 0.59%
18,000
+1,000
+6% +$167K
NVCR icon
60
NovoCure
NVCR
$1.87B
$2.7M 0.52%
32,000
-5,690
-15% -$459K
ANET icon
61
Arista Networks
ANET
$254B
$2.54M 0.49%
200,000
-88,000
-31% -$1.16M
BYND icon
62
Beyond Meat
BYND
$322M
$2.19M 0.42%
29,000
-17,800
-38% -$1.65M
LKFT
63
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
$1.96M 0.38%
9,500
-2,500
-21% -$462K
WCG
64
DELISTED
Wellcare Health Plans, Inc.
WCG
$1.55M 0.3%
+4,700
New +$1.41M
BMRN icon
65
BioMarin Pharmaceuticals
BMRN
$11.6B
$1.52M 0.29%
+18,000
New +$1.36M
ZM icon
66
Zoom
ZM
$29.4B
$1.36M 0.26%
20,000
– –
SRPT icon
67
CALL
Sarepta Therapeutics
SRPT
$1.7B
– –
0
– –
MRTX
68
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
0
– –
TLRY icon
69
PUT
Tilray
TLRY
$599M
– –
-3,000
Closed -$620K
MDCO
70
CALL
DELISTED
Medicines Co
MDCO
– –
-52,100
Closed -$3.47M
SWAV
71
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$1.06M 0.2%
+24,100
New +$890K
ALGT icon
72
Allegiant Air
ALGT
$2.86B
$1.04M 0.2%
+6,000
New +$993K
BBIO icon
73
BridgeBio Pharma
BBIO
$16.1B
$991K 0.19%
+28,300
New +$785K
PTCT icon
74
PTC Therapeutics
PTCT
$5.74B
$704K 0.14%
14,656
-10,552
-42% -$448K
QURE icon
75
uniQure
QURE
$3.03B
$573K 0.11%
+8,000
New +$439K
1 2
3
4

Similar funds

AGA
Arkos Global Advisors Houston, Texas $797M AUM 15.28% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $797M AUM 4.79% 1-Year Est. Return
LSA
L & S Advisors Los Angeles, California $795M AUM 52.77% 1-Year Est. Return
GWA
Geometric Wealth Advisors Washington, District of Columbia $799M AUM 22.19% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
SC
Soundwatch Capital Rowayton, Connecticut $793M AUM 15.45% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return

Atika Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Atika Capital Management held 98 positions worth $518M, up 9% from $475M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Atika Capital Management withdrew a net $57M in Q4 2019, closing 25 positions and reducing 22 holdings. Its most notable exit was Twitter, Inc., an estimated $8.32M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 24% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Atika Capital Management opened a new position in Reata Pharmaceuticals, Inc. Class A Common Stock worth $12.8M.

  • Atika Capital Management's largest Q4 2019 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 62,500 shares worth $12.8M.
  • Atika Capital Management added most to Enphase Energy in Q4 2019, an estimated $3.43M increase.
  • Atika Capital Management's biggest Q4 2019 reduction was Roku, cutting an estimated $5.36M.
  • Atika Capital Management fully exited Twitter, Inc. in Q4 2019, selling an estimated $8.32M.
  • Atika Capital Management's ten largest holdings make up 30% of its $518M portfolio in Q4 2019.
  • Atika Capital Management opened 21 new positions and closed 25 in Q4 2019.
  • Atika Capital Management's portfolio value rose 9% quarter-over-quarter to $518M.

Based on Atika Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.